Navigation Links
Adult Drug Effective in Treating Psoriasis in Children
Date:1/16/2008

Etanercept improved symptoms, quality of life for kids with moderate to severe disease,,,,

WEDNESDAY, Jan. 16 (HealthDay News) -- The drug etanercept significantly improved psoriasis symptoms in children under 17 with moderate to severe psoriasis, researchers are reporting.

The study found that 57 percent of the children and teens enrolled in the study had at least a 75 percent improvement in their symptoms, and their quality of life also improved.

"Psoriasis is not just some benign skin disease but can be truly life-altering for patients," said the study's lead author, Dr. Amy Paller, chairwoman of dermatology at Northwestern University's Feinberg School of Medicine.

"In our study, etanercept positively impacted quality of life," added Paller, who's also a pediatric dermatologist at Children's Memorial Hospital in Chicago.

Psoriasis is a common skin condition that causes the skin to grow at an accelerated rate. Because the skin cells are growing faster than they can be shed, scaly patches develop on the skin. The disorder tends to run in families, and doctors suspect it's an autoimmune disease, in which the body is mistakenly sensing that healthy cells are foreign substances. Nearly one-third of those with psoriasis also have what's known as psoriatic arthritis, according to the U.S. National Institutes of Health.

Mild cases of the disorder may respond to over-the-counter and prescription creams and ointments. But, for people with moderate to severe disease, stronger medications -- such as immune suppressants -- are often needed.

Newer medications, such as etanercept (Enbrel) and infliximab (Remicade), have been approved for treating psoriasis in adults. These medications, called biologics, specifically target the immune response, rather than dampen the entire immune system.

None of these medications has yet been approved for the treatment of children, however.

"This is the first trial that's been done in children and adolescents in this whole category of biologics for psoriasis," Paller said.

Etanercept is a tumor necrosis factor receptor (TNF). People with psoriasis have too much TNF, and entaercept reduces the amount of TNF. But, it can also lower the immune system's ability to fight infections.

To assess whether or not the drug was as safe and effective in children under 17 as it is in adults, Paller and her colleagues recruited 211 children and adolescents with moderate to severe psoriasis to participate in the trial.

Paller said the researchers chose etanercept, because it's already being used to treat children with juvenile rheumatoid arthritis and appears to be safe in that population.

The study volunteers, all between the ages of 4 and 17, were randomly assigned to receive 12 weeks of once-weekly injections of 0.8 milligrams (mg) of etanercept or a placebo. After the initial 12-week phase of the study, everyone was put on once-weekly etanercept for 24 weeks. Finally, at 36 weeks, 138 study volunteers were randomly chosen again to receive either etanercept or a placebo.

After 12 weeks, 57 percent of those on etanercept showed a 75 percent or greater improvement in their symptoms, compared with 11 percent on a placebo. During the 24 weeks when everyone received etanercept, 68 percent of those who had initially been on etanercept and 65 percent of those who started on a placebo showed a 75 percent or greater response.

During the second "randomized" portion of the trial, 42 percent of those placed on a placebo began having symptoms again.

Several children experienced infections while on etanercept, but all recovered without complications, according to the study.

"This is an incredible result," Paller said. "What's really exciting is we were worried because we were using a pretty low amount of etanercept. In adults who achieved the same blood levels of etanercept, there was a 30 to 34 percent response [of 75 percent or more]. Kids clearly are showing a better response than adults," she added.

The study was funded by Immunex, the manufacturer of Enbrel.

"This study was not a surprise. Etanercept has been approved for several years for psoriasis. It's very effective in adults and has a reasonably good safety record," said Dr. Mark Lebwohl, chairman of the medical advisory board of the National Psoriasis Foundation, and chairman of the department of dermatology at Mt. Sinai School of Medicine in New York City.

"Children with psoriasis grow up with a stigma; they get made fun of. Psoriasis has a profound psychological impact as well as a physical impact. Effective treatment really changes the lives of these kids in a very beneficial way," Lebwohl said.

More information

To learn more about psoriasis, visit the U.S. National Library of Medicine.



SOURCES: Amy Paller, M.D., chairwoman of dermatology, Feinberg School of Medicine, Northwestern University, and pediatric dermatologist, Children's Memorial Hospital, Chicago; Mark Lebwohl, M.D., chairman of the medical advisory board, National Psoriasis Foundation, and chairman, department of dermatology, Mt. Sinai School of Medicine, New York City; Jan. 17, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Air pollution linked to cardiovascular risk indices in healthy young adults
2. Urban Smog Tough on Young Adults Hearts
3. Heart Attacks at School Involve More Adults Than Kids
4. Governor Rendell Offers adultBasic Coverage to 35,000 Uninsured Pennsylvanians
5. Computer-Related Eye Strain Not Just for Adults
6. Adult offspring of parents with PTSD have lower cortisol levels
7. Rates of bipolar diagnosis in youth rapidly climbing, treatment patterns similar to adults
8. ADDAS Awareness Campaign Offers Resources and Education to Adults Living with AD/HD and Professionals Working With Them
9. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
10. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
11. Stem cells derived from adult testes produce wide range of tissue types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: